0001679628 2026-10-09 2026-10-09 0001679628 1 2026-10-09 2026-10-09 0001679628 2 2026-10-09 2026-10-09 0001679628 3 2026-10-09 2026-10-09 iso4217:USD pure shares S-8 S-8 EX-FILING FEES 0001679628 JUPITER NEUROSCIENCES, INC. N/A false false false S-8 JUPITER NEUROSCIENCES, INC. Equity Common stock, $0.0001 par value per share true 28749 2.44 70147.56 0.000087 6.10 Equity Common stock, $0.0001 par value per share true 19200 2.44 46848.00 0.000087 4.08 Equity Common stock, $0.0001 par value per share true 70000 2.44 170800.00 0.000087 14.86 287795.56 25.04 0.00 25.04 (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Jupiter Orphan Therapeutics, Inc. 2016 Equity Incentive Plan (the "2016 Plan"), the Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan (the "2021 Plan"), and the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock. (2) Represents shares of Common Stock reserved for issuance under the 2016 Plan. (3) Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The proposed maximum offering price per share and the maximum aggregate offering price are based on a price of $2.44 per share, which is the average of the high and low prices of the Registrant's Common Stock, as reported on the Nasdaq Capital Market, on October 5, 2026. (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Jupiter Orphan Therapeutics, Inc. 2016 Equity Incentive Plan (the "2016 Plan"), the Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan (the "2021 Plan"), and the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock. (4) Represents shares of Common Stock reserved for issuance under the 2021 Plan. (5) Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The proposed maximum offering price per share and the maximum aggregate offering price are based on a price of $2.44 per share, which is the average of the high and low prices of the Registrant's Common Stock, as reported on the Nasdaq Capital Market, on October 5, 2026. (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Jupiter Orphan Therapeutics, Inc. 2016 Equity Incentive Plan (the "2016 Plan"), the Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan (the "2021 Plan"), and the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock. (6) Represents shares of Common Stock reserved for issuance under the 2025 Plan. (7) Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act. The proposed maximum offering price per share and the maximum aggregate offering price are based on a price of $2.44 per share, which is the average of the high and low prices of the Registrant's Common Stock, as reported on the Nasdaq Capital Market, on October 5, 2026.